Barbara J. Kuter

6.2k total citations · 1 hit paper
99 papers, 3.9k citations indexed

About

Barbara J. Kuter is a scholar working on Epidemiology, Infectious Diseases and Hepatology. According to data from OpenAlex, Barbara J. Kuter has authored 99 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Epidemiology, 44 papers in Infectious Diseases and 33 papers in Hepatology. Recurrent topics in Barbara J. Kuter's work include Herpesvirus Infections and Treatments (36 papers), Hepatitis Viruses Studies and Epidemiology (32 papers) and Virology and Viral Diseases (26 papers). Barbara J. Kuter is often cited by papers focused on Herpesvirus Infections and Treatments (36 papers), Hepatitis Viruses Studies and Epidemiology (32 papers) and Virology and Viral Diseases (26 papers). Barbara J. Kuter collaborates with scholars based in United States, Japan and France. Barbara J. Kuter's co-authors include Holly Matthews, P. J. Provost, William J. Miller, David R. Nalin, C. J. White, Henry R. Shinefield, Keith S. Reisinger, Gary Calandra, Brian L. Wiens and Leora Brown and has published in prestigious journals such as New England Journal of Medicine, PEDIATRICS and Clinical Infectious Diseases.

In The Last Decade

Barbara J. Kuter

98 papers receiving 3.8k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience

2016 341 citations Barbara J. Kuter, Rituparna Das et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara J. Kuter United States	31	3.0k	1.1k	1.1k	709	652	99	3.9k
Aisha O. Jumaan United States	31	2.9k 1.0×	587 0.5×	893 0.8×	519 0.7×	641 1.0×	54	3.9k
Rafael Harpaz United States	40	5.1k 1.7×	739 0.6×	1.3k 1.1×	1.3k 1.9×	333 0.5×	95	6.9k
Mona Marin United States	29	3.1k 1.1×	528 0.5×	715 0.6×	762 1.1×	492 0.8×	93	3.5k
Paul Gargiullo United States	33	3.7k 1.3×	363 0.3×	1.9k 1.7×	782 1.1×	378 0.6×	73	5.9k
Melinda Wharton United States	30	2.4k 0.8×	389 0.3×	1.4k 1.2×	689 1.0×	356 0.5×	67	4.0k
Philip LaRussa United States	35	2.8k 0.9×	257 0.2×	1.1k 0.9×	298 0.4×	643 1.0×	123	3.9k
Dalya Güriş United States	25	3.8k 1.3×	327 0.3×	958 0.8×	503 0.7×	368 0.6×	42	4.5k
Graham Tipples Canada	32	2.7k 0.9×	1.2k 1.1×	1.7k 1.5×	209 0.3×	208 0.3×	106	4.0k
Nigel Gay United Kingdom	36	3.1k 1.0×	415 0.4×	786 0.7×	664 0.9×	173 0.3×	62	4.1k
Jane F. Seward United States	46	7.7k 2.6×	1.3k 1.2×	1.5k 1.4×	1.3k 1.9×	1.3k 2.0×	100	9.2k

Countries citing papers authored by Barbara J. Kuter

Since Specialization

Citations

This map shows the geographic impact of Barbara J. Kuter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara J. Kuter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara J. Kuter more than expected).

Fields of papers citing papers by Barbara J. Kuter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara J. Kuter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara J. Kuter. The network helps show where Barbara J. Kuter may publish in the future.

Co-authorship network of co-authors of Barbara J. Kuter

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara J. Kuter. A scholar is included among the top collaborators of Barbara J. Kuter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara J. Kuter. Barbara J. Kuter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Priddy, Frances, Spyros Chalkias, Brandon Essink, et al.. (2024). A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children. Expert Review of Vaccines. 23(1). 862–878. 6 indexed citations

Faig, Walter, Linda S. Gutierrez, Stella Winters, et al.. (2024). University students’ knowledge, perceptions, and sources of information on routinely recommended vaccines. Journal of American College Health. 73(9). 3644–3651. 2 indexed citations

Kuter, Barbara J., et al.. (2024). Perceptions of vaccine requirements among students at four Pennsylvania universities. Vaccine. 42(25). 126138–126138. 1 indexed citations

Green-McKenzie, Judith, Frances S. Shofer, Gregory Kruse, et al.. (2023). COVID-19 vaccine uptake before and after a vaccine mandate at a major academic hospital: Trends by race/ethnicity and level of patient contact. Vaccine. 41(37). 5441–5446. 3 indexed citations

Giuliano, Anna R., Barbara J. Kuter, Shari Pilon‐Thomas, et al.. (2023). Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients. Cancer Communications. 43(7). 749–764. 6 indexed citations

Green-McKenzie, Judith, Frances S. Shofer, Florence Momplaisir, et al.. (2021). Factors Associated With COVID-19 Vaccine Receipt by Health Care Personnel at a Major Academic Hospital During the First Months of Vaccine Availability. JAMA Network Open. 4(12). e2136582–e2136582. 23 indexed citations

Kuter, Barbara J., Gary S. Marshall, Jaime Fergie, Elvira Schmidt, & Manjiri Pawaskar. (2021). Prevention of measles, mumps and rubella: 40 years of global experience with M-M-R _II. Human Vaccines & Immunotherapeutics. 17(12). 5372–5383. 7 indexed citations

Kuter, Barbara J., Safa Browne, Florence Momplaisir, et al.. (2021). Perspectives on the receipt of a COVID-19 vaccine: A survey of employees in two large hospitals in Philadelphia. Vaccine. 39(12). 1693–1700. 100 indexed citations

Acosta, Camilo J., Stephanie O. Klopfer, Barbara J. Kuter, et al.. (2018). Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines. Human Vaccines & Immunotherapeutics. 15(2). 426–432. 4 indexed citations

10.

Manoff, Susan B., et al.. (2013). Burden of Varicella in Eastern Europe: A Systematic Review and Critical Analysis. Value in Health. 16(7). A342–A343. 1 indexed citations

11.

Lawrence, Jody, Shuangba He, Darcy A. Hille, et al.. (2012). A study of RotaTeq™ (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants. International Journal of Infectious Diseases. 16. e307–e307. 4 indexed citations

12.

Shinefield, Henry R., Steve Black, & Barbara J. Kuter. (2008). Varicella Immunogenicity with 1‐ and 2‐Dose Regimens of Measles‐Mumps‐Rubella‐Varicella Vaccine. The Journal of Infectious Diseases. 197(s2). S152–S155. 11 indexed citations

13.

Bernstein, Henry H., Karen Eves, Steven Black, et al.. (2007). Comparison of the Safety and Immunogenicity of a Refrigerator-Stable Versus a Frozen Formulation of ProQuad (Measles, Mumps, Rubella, and Varicella Virus Vaccine Live). PEDIATRICS. 119(6). e1299–e1305. 11 indexed citations

14.

Shinefield, Henry R., Wendy R. Williams, Colin D. Marchant, et al.. (2005). Dose-Response Study of a Quadrivalent Measles, Mumps, Rubella and Varicella Vaccine in Healthy Children. The Pediatric Infectious Disease Journal. 24(8). 670–675. 32 indexed citations

15.

Li, Shu, A. Chan, Holly Matthews, et al.. (2002). Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. The Pediatric Infectious Disease Journal. 21(4). 337–342. 88 indexed citations

16.

Lieberman, Jay M., Susan Partridge, Karen M. Kaplan, et al.. (2002). Kinetics of maternal hepatitis a antibody decay in infants: implications for vaccine use. The Pediatric Infectious Disease Journal. 21(4). 347–348. 26 indexed citations

17.

Reuman, Peter D., Mark H. Sawyer, Barbara J. Kuter, & Holly Matthews. (1997). Safety and immunogenicity of concurrent administration of measles-mumps-rubellavaricella vaccine and PedvaxHIB® vaccines in healthy children twelve to eighteen months old. The Pediatric Infectious Disease Journal. 16(7). 662–667. 16 indexed citations

18.

Nalin, David R., et al.. (1995). Monthly Update: Anti-infectives: VAQTA: Merck's hepatitis A vaccine, purified, inactivated. Expert Opinion on Investigational Drugs. 4(12). 1313–1319. 4 indexed citations

19.

Werzberger, Alan, Barbara J. Kuter, Daniel Shouval, et al.. (1993). Anatomy of a trial: a historical view of the Monroe inactivated hepatitis A protective efficacy trial. Journal of Hepatology. 18. S46–S50. 11 indexed citations

20.

White, C. J., Barbara J. Kuter, Catherine Hildebrand, et al.. (1991). Varicella Vaccine (VARIVAX) in Healthy Children and Adolescents: Results From Clinical Trials, 1987 to 1989. PEDIATRICS. 87(5). 604–610. 192 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact